

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Harrison Seth Loring</u>  (Last) (First) (Middle) C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350  (Street) SOUTH SAN FRANCISCO CA 94080  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Akero Therapeutics, Inc. [ AKRO ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/25/2022</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/25/2022		S		4,515	D	\$44.9163 <sup>(1)</sup>	300,851 <sup>(2)(3)</sup>	D	
Common Stock	10/25/2022		S		4,906	D	\$44.9163 <sup>(1)</sup>	326,813 <sup>(2)(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	10/26/2022		S		35,860	D	\$43.0756 <sup>(5)</sup>	264,991 <sup>(2)(3)</sup>	D	
Common Stock	10/26/2022		S		11,539	D	\$43.9749 <sup>(6)</sup>	253,452 <sup>(2)(3)</sup>	D	
Common Stock	10/26/2022		S		18,486	D	\$44.9002 <sup>(7)</sup>	234,966 <sup>(2)(3)</sup>	D	
Common Stock	10/26/2022		S		38,961	D	\$43.0756 <sup>(5)</sup>	287,852 <sup>(2)(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	10/26/2022		S		12,537	D	\$43.9749 <sup>(6)</sup>	275,315 <sup>(2)(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	10/26/2022		S		20,085	D	\$44.9002 <sup>(7)</sup>	255,230 <sup>(2)(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	10/27/2022		S		40,903	D	\$41.1156 <sup>(8)</sup>	194,063 <sup>(2)(3)</sup>	D	
Common Stock	10/27/2022		S		21,830	D	\$42.0299 <sup>(9)</sup>	172,233 <sup>(2)(3)</sup>	D	
Common Stock	10/27/2022		S		3,693	D	\$43.2321 <sup>(10)</sup>	168,540 <sup>(2)(3)</sup>	D	
Common Stock	10/27/2022		S		44,440	D	\$41.1156 <sup>(8)</sup>	210,790 <sup>(2)(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	10/27/2022		S		23,719	D	\$42.0299 <sup>(9)</sup>	187,071 <sup>(2)(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	10/27/2022		S		4,013	D	\$43.2321 <sup>(10)</sup>	183,058 <sup>(2)(3)</sup>	I	See Footnote <sup>(4)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$44.80 to \$45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4.
- The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional

